大葉大學圖書館 |

Melatonin, neuroprotective agents and antidepressant therapy[electronic resource] /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	615.78
書名/作者:	Melatonin, neuroprotective agents and antidepressant therapy/ edited by Francisco Lopez-Munoz ... [et al.].
其他作者:	Lopez-Munoz, Francisco.
出版者:	New Delhi : : Springer India :, 2016.
面頁冊數:	xxv, 921 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Melatonin.
標題:	Melatonin - Therapeutic use.
標題:	Antidepressants.
標題:	Medicine.
標題:	Internal medicine.
標題:	Neurology.
標題:	Psychopharmacology.
標題:	Medicine & Public Health.
標題:	Internal Medicine.
ISBN:	9788132228035
ISBN:	9788132228011
摘要、提要註:	This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects.
電子資源:	http://dx.doi.org/10.1007/978-81-322-2803-5

Melatonin, neuroprotective agents and antidepressant therapy[electronic resource] /
Melatonin, neuroprotective agents and antidepressant therapy[electronic resource] /edited by Francisco Lopez-Munoz ... [et al.]. - New Delhi :Springer India :2016. - xxv, 921 p. :ill., digital ;24 cm.

This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects.

ISBN: 9788132228035

Standard No.: 10.1007/978-81-322-2803-5doiSubjects--Topical Terms:

558582
Melatonin.

LC Class. No.: RM297.M44

Dewey Class. No.: 615.78

Melatonin, neuroprotective agents and antidepressant therapy[electronic resource] /
LDR:02491nam a2200301 a 4500 001 476738
003 DE-He213
005 20161117101939.0
006 m d
007 cr nn 008maaau
008 181208s2016 ii s 0 eng d
020 $a 9788132228035 $q (electronic bk.)
020 $a 9788132228011 $q (paper)
024 7 $a 10.1007/978-81-322-2803-5 $2 doi
035 $a 978-81-322-2803-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RM297.M44
072 7 $a MJN $2 bicssc
072 7 $a MED056000 $2 bisacsh
082 0 4 $a 615.78 $2 23
090 $a RM297.M44 $b M517 2016
245 0 0 $a Melatonin, neuroprotective agents and antidepressant therapy $h [electronic resource] / $c edited by Francisco Lopez-Munoz ... [et al.].
260 $a New Delhi : $b Springer India : $b Imprint: Springer, $c 2016.
300 $a xxv, 921 p. : $b ill., digital ; $c 24 cm.
520 $a This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects.
650 0 $a Melatonin. $3 558582
650 0 $a Melatonin $x Therapeutic use. $3 614997
650 0 $a Antidepressants. $3 487117
650 0 $a Medicine. $3 373206
650 0 $a Internal medicine. $3 206007
650 0 $a Neurology. $3 402687
650 0 $a Psychopharmacology. $3 372108
650 1 4 $a Medicine & Public Health. $3 463493
650 2 4 $a Internal Medicine. $3 341979
700 1 $a Lopez-Munoz, Francisco. $3 687742
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-81-322-2803-5
950 $a Medicine (Springer-11650)